The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Angiomotin
Open accessAbstract
Angiostatin, a circulating inhibitor of angiogenesis, was identified by its ability to maintain dormancy of established metastases in vivo. In vitro, angiostatin inhibits endothelial cell migration, proliferation, and tube formation, and induces apoptosis in a cell type–specific manner. We have used a construct encoding the kringle domains 1–4 of angiostatin to screen a placenta yeast two-hybrid cDNA library for angiostatin-binding peptides. Here we report the identification of angiomotin, a novel protein that mediates angiostatin inhibition of migration and tube formation of endothelial cells. In vivo, angiomotin is expressed in the endothelial cells of capillaries as well as larger vessels of the human placenta. Upon expression of angiomotin in HeLa cells, angiomotin bound and internalized fluorescein-labeled angiostatin. Transfected angiomotin as well as endogenous angiomotin protein were localized to the leading edge of migrating endothelial cells. Expression of angiomotin in endothelial cells resulted in increased cell migration, suggesting a stimulatory role of angiomotin in cell motility. However, treatment with angiostatin inhibited migration and tube formation in angiomotin-expressing cells but not in control cells. These findings indicate that angiostatin inhibits cell migration by interfering with angiomotin activity in endothelial cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Holmgren, L., O'Reilly, M. S., & Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0295-149 · Cited by 1,878
Self-citationAngiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Self-citationGood, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., & Bouck, N. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6624 · Cited by 1,054
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1
Jiménez, B., Volpert, O. V., Crawford, S. E., Febbraio, M., Silverstein, R. L., & Bouck, N. (2000) · Nature Medicine · doi:10.1038/71517 · Cited by 1,020
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Endostatin Induces Endothelial Cell Apoptosis
Dhanabal, M., Ramchandran, R., Waterman, M. J. F., Lu, H., Knebelmann, B., Segal, M., & Sukhatme, V. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11721 · Cited by 584
Angiostatin binds ATP synthase on the surface of human endothelial cells
Moser, T. L., Stack, M. S., Asplin, I., Enghild, J. J., Højrup, P., Everitt, L., Hubchak, S., Schnaper, H. W., & Pizzo, S. V. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2811 · Cited by 526
Cited by
Tumorigenesis and the angiogenic switch
Bergers, G., & Benjamin, L. E. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1093 · Cited by 3,559
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Matrix metalloproteinases and angiogenesis
Rundhaug, J. E. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00355.x · Cited by 960
Impairment of angiogenesis and cell migration by targeted aquaporin-1 gene disruption
Saadoun, S., Papadopoulos, M. C., Hara-Chikuma, M., & Verkman, A. S. (2005) · Nature · doi:10.1038/nature03460 · Cited by 728
The Mammalian Blood-Testis Barrier: Its Biology and Regulation
Mruk, D. D., & Cheng, C. Y. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1101 · Cited by 680
Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
Zhao, B., Li, L., Lu, Q., Wang, L. H., Liu, C.-Y., Lei, Q., & Guan, K.-L. (2011) · Genes & Development · doi:10.1101/gad.2000111 · Cited by 665
Errani, C., Zhang, L., Sung, Y. S., Hajdu, M., Singer, S., Maki, R. G., Healey, J. H., & Antonescu, C. R. (2011) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20886 · Cited by 553
Endogenous Inhibitors of Angiogenesis
Nyberg, P., Xie, L., & Kalluri, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2427 · Cited by 553
Hippo Pathway-independent Restriction of TAZ and YAP by Angiomotin
Chan, S. W., Lim, C. J., Chong, Y. F., Pobbati, A. V., Huang, C., & Hong, W. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.212621 · Cited by 386
Gonzalez-Avila, G., Sommer, B., Mendoza-Posada, D. A., Ramos, C., Garcia-Hernandez, A. A., & Falfan-Valencia, R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.02.010 · Cited by 373
A Rich1/Amot Complex Regulates the Cdc42 GTPase and Apical-Polarity Proteins in Epithelial Cells
Wells, C. D., Fawcett, J. P., Traweger, A., Yamanaka, Y., Goudreault, M., Elder, K., Kulkarni, S., Gish, G., Virag, C., Lim, C., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.045 · Cited by 372
Salvucci, O., Yao, L., Villalba, S., Sajewicz, A., Pittaluga, S., & Tosato, G. (2002) · Blood · doi:10.1182/blood.v99.8.2703 · Cited by 347
Modeling the early stages of vascular network assembly
Serini, G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg176 · Cited by 322
Vascularization—The Conduit to Viable Engineered Tissues
Kaully, T., Kaufman-Francis, K., Lesman, A., & Levenberg, S. (2009) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2008.0193 · Cited by 317
The Parafibromin Tumor Suppressor Protein Is Part of a Human Paf1 Complex
Rozenblatt-Rosen, O., Hughes, C. M., Nannepaga, S. J., Shanmugam, K. S., Copeland, T. D., Guszczynski, T., Resau, J. H., & Meyerson, M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.2.612-620.2005 · Cited by 285
Angiomotin-like Proteins Associate with and Negatively Regulate YAP1
Wang, W., Huang, J., & Chen, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.c110.205401 · Cited by 269
Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype
Almog, N., Ma, L., Raychowdhury, R., Schwager, C., Erber, R., Short, S., Hlatky, L., Vajkoczy, P., Huber, P. E., Folkman, J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2590 · Cited by 240
“Angiomotin was found to mediate the antiangiogenic activity of the endogenous angiogenesis inhibitor angiostatin (17, 20), which was shown to suppress tumor growth and maintain dormancy of tumor metastases (21, 22).”
BackgroundThe Angiomotins – From discovery to function
Moleirinho, S., Guerrant, W., & Kissil, J. L. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.006 · Cited by 112
Metadata
- Authors
- Troyanovsky, B., Levchenko, T., Månsson, G., Matvijenko, O., & Holmgren, L.
- Venue
- The Journal of Cell Biology
- Publisher
- Rockefeller University Press
- Published
- 2001-03-19
- Volume
- 152
- Issue
- 6
- Pages
- 1247-1254
- ISSN
- 0021-9525 (ISSN-L)
- 1540-8140
- OpenAlex
- W2010589579
- Cited by
- 383
- References
- 26
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.